Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ferric citrate vs sevelamer for serum phosphate control in hemodialysis patients
CTR20190978Phase 3Completed
- Sponsor
- Taizhou Langrun Pharmaceutical
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ferric citrate in hyperphosphatemia, chronic kidney disease (CKD), end-stage kidney disease (ESKD), sponsored by Taizhou Langrun Pharmaceutical. Started May 2019; status: completed.
02
Drugs
ferric citrate
03
Conditions
hyperphosphatemiachronic kidney disease (CKD)end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on CTR20190978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190978.